We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Allergan has clinched FDA approval for its hypertension treatment Byvalson, the first fixed-dose combination of a beta blocker and angiotensin II receptor blocker in the U.S. Read More
A second FDA complete response letter to Adamis Pharmaceuticals for its acute anaphylaxis candidate requests an extension of its human factors and reliability studies. Read More